Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial

(2014) Takashi Kadowaki et al.   ADVANCES IN THERAPY

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

(2014) Bernard Zinman et al.   Cardiovascular Diabetology

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis

(2014) William L. Baker et al.   Journal of the American Society of Hypertension

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes

(2013) Giovanni Sartore et al.   ACTA DIABETOLOGICA

Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes

(2013) R. Peter et al.   DIABETES & METABOLISM

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Global estimates of diabetes prevalence for 2013 and projections for 2035

(2013) L. Guariguata et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan

(2013) Yehuda Handelsman et al.   Endocrine Practice

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

(2013) Shigeto Kanada et al.   Journal of Diabetes Investigation

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes: A nationwide population-based study

(2012) P.-F. Hsu et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes

(2011) Gong Su et al.   Cardiovascular Diabetology

Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up: Lessons from the San Luigi Gonzaga Diabetes Study

(2011) F. Cavalot et al.   DIABETES CARE

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes

(2010) A. H. Barnett et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Revised Equations for Estimated GFR From Serum Creatinine in Japan

(2009) Seiichi Matsuo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

(2009) I. Raz et al.   DIABETES CARE

Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients

(2008) A. Ceriello et al.   DIABETES

Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study

(2008) C. S. Fox et al.   DIABETES CARE

Self-reported Diabetes Mellitus and Risk of Mortality from All Causes, Cardiovascular Disease, and Cancer in Takayama: A Population-based Prospective Cohort Study in Japan

(2008) Shino Oba et al.   JOURNAL OF EPIDEMIOLOGY